Triggered by the Covid-19 pandemic, we have developed Bentrio™ (AM-301), a nasal spray to help protect against airborne viruses, allergens and potentially other harmful particles which are inhaled through the nose. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio™ was shown to reduce the infectious viral load by more than 99% when used for prevention. Clinical testing of the nasal spray has demonstrated its utility also in case of allergic rhinitis. Further studies to expand our knowledge about the utility of Bentrio™ for risk mitigation and self-protection are ongoing or planned.